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BACKGROUND: Ischemic heart disease is a leading cause of heart failure 
and despite advanced therapeutic options, morbidity and mortality rates 
remain high. Although acute inflammation in response to myocardial cell 
death has been extensively studied, subsequent adaptive immune activity 
and anti-heart autoimmunity may also contribute to the development of 
heart failure. After ischemic injury to the myocardium, dendritic cells (DC) 
respond to cardiomyocyte necrosis, present cardiac antigen to T cells, and 
potentially initiate a persistent autoimmune response against the heart. 
Cross-priming DC have the ability to activate both CD4+ helper and CD8+ 
cytotoxic T cells in response to necrotic cells and may thus be crucial 
players in exacerbating autoimmunity targeting the heart. This study 
investigates a role for cross-priming DC in post–myocardial infarction 
immunopathology through presentation of self-antigen from necrotic 
cardiac cells to cytotoxic CD8+ T cells.
METHODS: We induced type 2 myocardial infarction–like ischemic injury 
in the heart by treatment with a single high dose of the β-adrenergic 
agonist isoproterenol. We characterized the DC population in the 
heart and mediastinal lymph nodes and analyzed long-term cardiac 
immunopathology and functional decline in wild type and Clec9a-
depleted mice lacking DC cross-priming function.
RESULTS: A diverse DC population, including cross-priming DC, is present 
in the heart and activated after ischemic injury. Clec9a−/− mice deficient 
in DC cross-priming are protected from persistent immune-mediated 
myocardial damage and decline of cardiac function, likely because of 
dampened activation of cytotoxic CD8+ T cells.
CONCLUSION: Activation of cytotoxic CD8+ T cells by cross-priming DC 
contributes to exacerbation of postischemic inflammatory damage of the 
myocardium and corresponding decline in cardiac function. Importantly, 
this provides novel therapeutic targets to prevent postischemic 
immunopathology and heart failure.
Cross-Priming Dendritic Cells Exacerbate 
Immunopathology After Ischemic Tissue 
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Heart failure (HF) is a common long term compli-cation of myocardial infarction (MI) affecting up to 62% of MI patients1 and >37.7 million peo-
ple worldwide.2 There is no cure and 5-year mortality 
rates rival those of many cancers.3 An MI is defined 
as cardiac tissue damage attributable to insufficient 
oxygen supply to parts of the myocardium and is fur-
ther divided into type 1 MI (T1MI), type 2 MI (T2MI), 
and myocardial injury.4,5 T1MI occurs after disruption 
of an atherosclerotic plaque leads to a blockade of 
coronary blood flow, while T2MI is a heterogeneous 
syndrome where other conditions including hypoten-
sion, anemia, respiratory failure, tachycardia, severe 
hypertension, or sepsis lead to an imbalance between 
oxygen supply and demand.6,7 T2MI is an underrecog-
nized clinical entity with a prevalence of up to 58% 
of all MI patients.8 Notably, these patients have poor 
short- and long-term outcomes9 with a HF risk equal 
to T1MI patients.1,10
A timely immune response to myocardial damage 
plays a crucial role in endogenous repair processes and 
tissue maintenance. However, excessive tissue necro-
sis can lead to persistent inflammation, fibrosis, and a 
break in immunologic self-tolerance, leading to long 
lasting adaptive immune autoreactivity.11–15 Anti-heart 
autoantibodies against cardiac epitopes are a well-
known clinical phenomenon during HF,16 and the 
pathogenic function of autoreactive T cells after MI has 
recently been demonstrated.17,18 Antigen-specific T and 
B cells can be long-lived and have been suggested to 
cause ongoing low-level tissue destruction,19,20 hamper 
regenerative efforts, and exacerbate the development 
toward heart failure.21,22
Dendritic cells (DC) play a central role in triggering 
autoimmunity. They are considered the most efficient 
antigen-presenters, linking the innate with the adap-
tive immune response by processing antigens, present-
ing them to T cells via major histocompatibility complex 
(MHC):T cell receptor recognition and defining the re-
sulting T cell functional phenotype depending on in-
flammatory context.23 The DC population has been re-
ported to be involved in the post-MI immune response 
in rodent T1MI models.24 Notably, a recent study using 
highly specific depletion of DC via Zbtb46 elegantly 
showed reduced post-MI infarct size, improved systolic 
function, and reduced total T cell numbers in the isch-
emic tissue.25
Importantly, the total DC population is highly heter-
ogenous. While classic antigen presentation is mediat-
ed by the interaction between antigenic peptide-bound 
MHC II molecules with their cognate T cell receptor on 
CD4+ helper T cells,26 a subpopulation of DC (classical 
DC1) has the distinct ability to present antigen to both 
CD4+ helper and CD8+ cytotoxic T cells.27 This “cross-
priming” activity is a powerful boost for adaptive im-
mune responses and has been exploited for improved 
anticancer vaccines.28 However, in a situation of ne-
crotic tissue injury such as cardiomyocyte cell death, DC 
cross-priming of cardiac antigen to cytotoxic CD8+ T 
cells may exacerbate long-term autoimmune-mediated 
tissue damage.
To explore the role of the cross-priming subset of 
classical DC (cDC1) in immune-mediated myocardial 
deterioration after ischemic tissue damage, we show 
here that cross-priming DC are present in the heart and 
activated after ischemic injury. Genetic depletion of the 
C-type lectin-like receptor gene Clec9a, which enables 
DC cross-priming, decreases long-term myocardial im-
munopathology, protects from decline of cardiac func-
tion, and suppresses the activation of cytotoxic CD8+ T 
cells.
MATERIALS AND METHODS
An expanded methods section is available in the Data 
Supplement.
Data Availability
The accession number for the single cell sequencing data 
reported in this paper is ArrayExpress E-MTAB-7895.29 All 
other data, methods, R scripts,  and materials that support 
Clinical Perspective
What Is New?
• This is the first report implicating the cross-priming 
function of dendritic cells in immunopathology 
after type 2 myocardial infarction, including inflam-
mation, fibrosis, and functional decline.
• Myocardial injury leads to local infiltration and acti-
vation of cross-priming dendritic cells, which acti-
vate cytotoxic T cells that infiltrate the heart.
• Depletion of the dendritic cell cross-priming 
function inhibits accumulation and activation of 
cytotoxic T cells and stops myocardial immunopa-
thology and functional decline.
What Are the Clinical Implications?
• Cross-priming dendritic cells are activated early as 
part of the acute immune response after myocar-
dial infarction yet have a long-lasting legacy by trig-
gering activation of a persistent adaptive response 
in the form of cytotoxic T cells.
• We show that elevated levels of cytotoxic T cells 
are present in remote areas of human heart failure 
hearts, where they are highly likely to induce myo-
cardial necrosis.
• With cross-priming, we provide a targetable path-
way to prevent activation of T cell cytotoxicity and 
persistent post–myocardial infarction immunopa-
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the findings of this study are available from the authors on 
request.
Mice
All animal procedures were approved by the Imperial College 
Governance Board for Animal Research and the Home Office 
(UK) and The Jackson Laboratory Institutional Animal Care and 
Use Committee, respectively. Mouse strains used in this study 
were B6(Cg)-Clec9atm1.1Crs/J (CLEC9a−/−), B6.129S2-Cd8atm1Mak/J 
(CD8−/−), and C57BL/6J (wild type [WT]). T1MI was induced 
by permanent ligation of the left anterior descending artery 
as previously described30 in male and female mice 10 to 12 
weeks of age. T2MI was induced by a single intraperitoneal 
injection at a dose of 160 mg/kg isoproterenol HCL (Sigma-
Aldrich, St. Louis, MO), as described previously.31 Monitoring 
of cardiac function was performed by transthoracic echocar-
diography by a blinded operator using a high-frequency ultra-
sound system Vevo 770 (VisualSonics Inc., Toronto, Canada) 
with a 30-MHz linear transducer.
Human Tissue
All work was carried out under the Human Tissue Act 2004 
and conformed with the principles of the Declaration of 
Helsinki. Tissue and clinical data were fully anonymized 
before being handed  to researchers. Human left ventricu-
lar (LV) tissue was obtained from hearts of end-stage heart 
failure patients removed during transplant surgery (Research 
Ethics Committee approval: 09/H0504/104+5; Biobank 
approval number: NP001-06-2015). Donor hearts unsuitable 
for transplantation were used as controls (Research Ethics 
Committee approval: 16/LO/1568). Informed consent was 
obtained from patients or next of kin. For detection of CD3+ 
and CD8+ T cells in heart failure hearts, frozen sections of 
human heart tissue were stained with mouse anti-human 
CD3 (clone UCHT1 at 1:100), and mouse anti-human CD8 
(clone HIT8a at 1:100) with Alexa Fluor 488 goat anti-mouse 
IgG (poly4053 at 1:500; all purchased from BioLegend, 
London, UK).
Single Cell Sequencing
Single cell RNA sequencing of MI hearts was performed as 
part of a previous study29 using the 10× Chromium platform 
with v2 chemistry and analyzed using Seurat software pack-
age version 3.032 in R version 3.6.2.33 All sequencing data are 
available in the Array Express repository (accession number 
EMTAB-7895).
Histology and Immunofluorescence 
Staining
Hearts were excised after perfusion and processed for stan-
dard hematoxylin and eosin and Picrosirius red histological 
stains. Semiquantitative scoring was performed, as previ-
ously established.34 For CD8 immunohistochemistry, sec-
tions were stained with rat anti-mouse CD8 (14-0808-80 at 
1:1000; Invitrogen; Thermo Fisher Scientific, Rochford, UK) 
and rabbit anti-rat horseradish peroxidase (AI-4001 at 1:50; 
Vector Laboratories, Peterborough, UK) with hematoxylin 
as nuclei counterstain. Image analysis and acquisition was 
performed using a Hamamatsu NanoZoomer 2.0 slide scan-
ner (Hamamatsu, San Jose, CA), a LMD7000 microscope 
(Leica Microsystems, Milton Keynes, UK), NDP.view2 Plus 
Image viewing software (Hamamatsu) and public domain 
software ImageJ (http://rsb.info.nih.gov; National Institutes 
of Health),35 and QuPath open source bioimage analysis 
software (https://qupath.readthedocs.io/en/latest/index.
html#).36
Langendorff Perfusion and Optical 
Mapping
Experiments were performed as previously described.37,38 
Briefly, explanted hearts were perfused and superfused 
with modified Tyrode’s solution (in mM: 130 NaCl, 5.4 
KCl, 0.3 NaH2PO4, 1 MgCl2, 10 HEPES, 18 CaCl2, and 10 
D-Glucose, [pH 7.4]) ECGs were recorded during all experi-
ments using LabChart 8 software in conjunction with 
Powerlab and BioAmp systems (ADInstruments Pty Ltd, UK) 
and programmed electric stimulation protocols were car-
ried out via the pacing electrode at the left ventricle using 
a stimulator (MicroPace, USA). For optical mapping of 
transmembrane voltage, an excitation-contraction uncou-
pler, blebbistatin (5 μM), and voltage sensitive dye, Di-4-
ANNEPS (5 μM) were administered to the heart and signals 
recorded using complimentary metal-oxide semiconductor 
cameras (RedShirtImaging LLC, USA). ECG recordings and 
optical recordings were analyzed using methods previously 
described.37,38
Cardiac Troponin I ELISA
A mouse cardiac troponin I ELISA Kit (MyBioSource, San 
Diego, CA) was used to assess cardiac troponin I levels in 
post-MI serum according to the manufacturer’s instructions.
Tissue Digestion and Flow Cytometry
To generate single-cell suspensions for flow cytometry, 
a modified digestion protocol was used as previously 
described.39 Cell suspensions were stained with a previously 
established flow cytometry panel.31 Samples were acquired 
using a BD FACSymphony A5 (Becton Dickinson) and ana-
lyzed using FlowJo 10.2 (Treestar, Ashland, OR) software 
(www.flowjo.com).
Experimental Planning and Statistical 
Analysis
Experimental design of in vivo mouse studies was guided 
by the recommendations of the National Centre for the 
Replacement, Refinement and Reduction of Animals in 
Research.40 Statistical analysis was performed using SPSS or 
GraphPad Prism 6 and data were presented as mean±SEM 
throughout. Comparison between 2 groups was performed 
using Student t test. Comparison between multiple experi-
mental groups was performed using 1- or 2-way ANOVA with 
multiple comparisons post hoc tests to obtain multiplicity-
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RESULTS
Ischemic Injury to the Heart Activates 
Dynamic Changes in the Myocardial DC 
Population 
Single cell RNA sequencing identified an expectedly 
heterogenous DC population in the mouse heart, 
both at baseline and over time after myocardial isch-
emic injury. Myocardial injury was induced by surgi-
cal ligation of the left anterior descending artery and 
single cell RNA sequencing was performed on 51 687 
single, live, nucleated interstitial (noncardiomyocyte) 
cells, using the 10× Chromium v2 technology41 as de-
scribed previously29 (Figure 1A). Unbiased clustering 
defined a distinct population of H2-Ab1+, Cd209a+ 
cells as DC (Figure  1B and 1C). This classification 
was confirmed by comparing the expression levels 
of bona fide DC markers  and markers shared with 
other antigen-presenting cells (B cells, monocyte/
macrophages) across all cell populations (Figure 1D). 
Unbiased clustering further split the DC population 
into 5 subclusters (Figure 1E). These included CD103 
(Itgae)- CD11b (Itgam)+ classical DC1 (cDC1), CD103 
(Itgae)+ CD11b (Itgam)- cDC2, monocytes/monocyte-
derived DC, plasmacytoid DC, and a small population 
of “activated DC.” Activated DC are characterized 
by markers upregulated in response to stimulation, 
such as Cacnb3,42 Ccr7, Il12b involved in priming Th1 
and cytotoxic T cell responses, and features of migra-
tory DC (eg, Fscn-1, Cd200, Cd27443; Figure 1F). Of 
particular interest in a setting of necrotic tissue in-
jury was the presence of cDC1 cells, which expressed 
genes involved in cross-presentation of endogenous 
antigens including Xcr1 and Clec9a (Figure  1F). As 
previously shown in left anterior descending artery li-
gation-induced myocardial necrosis,44 the number of 
DC increased after MI reaching a striking 2% of the 
total noncardiomyocyte cell population 1 week af-
ter MI before returning to near baseline levels. cDC1 
constituted the majority of DC at baseline (57%) and 
again after week 2 (54%) once acute infiltration of 
monocytes/monocyte-derived DC had resolved (Fig-
ure 1G).
Interestingly, we also observed a predominance 
of cytotoxic Cd8+ over Cd4+ helper T cells and a no-
table proportion of Cd8-Cd4- double negative T cells 
within the Cd3+ cell population in the T cells clus-
ter (Figure 1H and 1I). These were negative for Ncr1, 
which excludes an NKT phenotype (Figure  1I). The 
biological significance of these cells is currently un-
der investigation. These observations prompted us to 
further study DC activation after ischemic injury in 
the heart, and potential effects of cross-priming DC 
on postischemic autoimmune-mediated damage and 
the cytotoxic CD8+ T cell population.
Ischemic Injury Leads to an Increase in 
Activated and XCR1+ Cross-Priming DC in 
the Myocardium and the Heart-Draining 
Mediastinal Lymph Nodes 
To test the generality of the DC response to cardiac 
insult, T2MI-like necrotic lesions in the myocardium 
were induced by a single intraperitoneal injection of 
isoproterenol. This treatment regime was previously 
optimized for C57Bl/6J mice31 and induced myocardial 
histopathology reminiscent of T2MI, including inflam-
matory lesions (Figure  2A) and replacement fibrosis 
(Figure  2B). Single cell suspensions obtained from di-
gested ventricular tissue and heart-draining mediastinal 
lymph nodes were analyzed for the presence of cDC 
at baseline, weeks 1, 2, and 4 after injury. cDC were 
defined by flow cytometry as CD45+CD3-CD19-Ly6G-
Ly6C-CD11c+ (Figure I in the Data Supplement). Consis-
tent with the above single cell RNAseq results, the total 
number of CD11c+Ly6C- cDC cells per milligram ventric-
ular tissue was increased in the heart 1 week after injec-
tion and subsequently returned to baseline numbers. In 
contrast, the relative proportions of lymph node cDC 
did not change significantly (Figure 2C). MHC-II expres-
sion on DC is an indicator for their maturation state 
and antigen presenting capacity.45,46 Comparable with 
total cDC numbers, the number of MHC-II expressing 
cells also increased quickly after isoproterenol injection 
(Figure  2D) indicating a heightened maturation state 
and increased capacity for antigen presentation within 
the cardiac cDC population (Figure 2E). Again, no sig-
nificant change in cDC composition was observed in 
mediastinal lymph nodes of isoproterenol-treated mice.
Subsequently, we used XCR1 as marker to discrimi-
nate cDC1 (CD11b-XCR1+) from cDC2 (CD11b+XCR1-) 
among total cDC, as XCR1 is expressed on both pe-
ripheral and lymphatic tissue cDC1 but is absent from 
cDC2.47 In the heart, the CD11c+Ly6c- cDC population 
consisted of CD11b+XCR1- cDC2 and CD11b-XCR1+ 
cDC1 (Figure 2F). A small proportion of CD11b-XCR1- 
cells was observed which did not change over time. 
cDC1 numbers increased significantly in the heart (num-
bers per milligram tissue) but not in the lymph node 
(percent of total cDC; Figure 2G). Importantly, in both 
the heart and the lymph node, cDC1 cells upregulated 
MHC-II expression indicating an increased maturation 
state and higher antigen-presentation ability. Important-
ly, besides an overall increase in the number of MHC-II 
positive DC, the cDC1 subpopulation (CD11c+CD11b-
XCR1+) also upregulated antigen-presentation function 
as seen via an increase in MHC-II mean fluorescent in-
tensity levels (Figure 2H).
These results confirm that the cross-priming cDC1 
population is activated in response to myocardial tissue 
injury, which may provide the critical first step for induc-
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Blockade of DC Cross-Priming by Genetic 
Depletion of Clec9a Allows More 
Efficient Resolution of Postischemic 
Inflammation and Immunopathology
To confirm a role of DC cross-priming in the immune 
response to cardiac injury, we made use of mice 
lacking the gene encoding CLEC9A (C-type lectin-
like receptor 9A)/DNGR-1 (dendritic cell natural killer 
lectin group receptor 1)/CD370, a receptor essential 
for processing antigens from necrotic cells for cross-
priming of cytotoxic CD8+ T cells.48 Clec9a−/− mice ex-
press green-fluorescent protein under the control of 
the Clec9a promotor. This confirmed the specificity 
Figure 1. DC and T cells after ischemic injury in the heart.
A, Experimental approach used to obtain the single cell RNA sequencing dataset. Mouse cardiac interstitial cells were isolated by mechanical and enzymatic dis-
sociation of adult mouse cardiac ventricular tissue at homeostasis and over time post–myocardial infarction. Single, live, nucleated interstitial cells were used for 
the 10× Chromium analysis; 51 687 were captured and sequenced. B, UMAP plots highlighting DC in orange, and T and NK cells in blue. C, Dot plot showing top 
marker genes for each lineage. The size scale is proportional to the percentage of expressing cells; color scale indicates average expression intensity. D, Heatmap 
comparing the expression level of B cells/DC/macrophage marker genes across all populations. E, UMAP showing the DC subclusters (897 cells). F, Heatmap of 
top marker genes for each DC subpopulation. G, Quantification of DC among total cells and relative frequency of DC subpopulations at homeostasis and different 
time points post–myocardial infarction. H, Feature plots showing the expression of Cd3g, Cd4, Cd8a and Ncr1 in a subset of cells defined by Cd3g expression 
(1040 cells). I, Quantification of Cd4+, Cd8a+, Ncr1+ and DN cells within the Cd3g+ fraction of the NK and T cell cluster. actDC indicates activated DC; cDC1, 
classical DC1; cDC2, classical DC2; DC, dendritic cells; DN, double negative; EC, endothelial cells; MFC, matrifibrocytes; moDC, monocytes/monocyte-derived; NK, 
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of CLEC9A expression for XCR1+ DC (Figure II in the 
Data Supplement). While granulocytes, and in particu-
lar a small proportion of eosinophils, appear to express 
some CLEC9A, the vast majority and by far highest 
expression was detected in cDC1.
Myocardial damage induced by a single dose of 
isoproterenol was assessed by semiquantitative scor-
ing and quantification of immunopathology/immune 
cell infiltration and collagen deposition as described 
previously.34 Results were consistent between high 
throughput semiquantitative scores, which allow reli-
able assessment of the disruption of healthy cardiac his-
tomorphology attributable to immune cell clusters and 
inflammation-associated edema, and quantitative im-
age analysis, which affords accurate cell/nuclei counts 
and measures of collagen area (Figure III in the Data 
Supplement). Thus, subsequent analysis was performed 
using semiquantitative scoring.
Both Clec9a−/− and WT mice reacted to isoproter-
enol treatment with an equal increase in serum tropo-
nin levels 24 hours after injection (Figure 3A), mono-
nuclear infiltration, and fibrosis in the myocardium 
(Figure  3B). Strikingly, however, myocardial histology 
of isoproterenol-treated Clec9a−/− mice was indistin-
guishable from untreated controls by week 4, while 
immunopathology and fibrosis persisted until week 6 
Figure 2. Type 2 myocardial infarction–like myocardial injury activates the DC population in the heart and the heart-draining lymph nodes.
C57BL/6J mice were treated with 160 mg/kg isoproterenol to induce T2MI-like myocardial injury and flow cytometry was performed on a single cell preparation of the 
heart and mediastinal lymph nodes. A and B, Example micrographs (modified from Hasham et al34) of isoproterenol-induced myocardial histopathology as assessed by 
hematoxylin and eosin staining for immunopathology (A) and Picrosirius red staining for fibrosis (B). C, Flow cytometry contour plots showing the gating for CD11c+ 
population among total CD45+ and corresponding quantification of cells/mg tissue (heart) or percent of total CD45+ cells (lymph node). D, Representative contour 
plots of CD11b and MHC-II staining in the CD11c+ population of hearts and lymph nodes of isoproterenol-treated versus control mice and corresponding quantifica-
tion of CD11c+MHC-II+ cells/mg tissue (heart) or as percent of total CD11c+ cells (lymph node). E, Composition of the CD11c+ cell population in heart and lymph nodes 
based on CD11b and MHC-II expression. F, Representative contour blots of CD11b and XCR1 staining within the CD11c+ population of hearts and lymph nodes of 
isoproterenol-treated versus control mice and corresponding quantification of CD11b-XCR1+ cells/mg tissue (heart) or as percent of total CD11c+ cells (lymph node). 
G, Composition of the CD11c+ cell population in heart and lymph nodes based on CD11b and XCR1 expression. H, Levels of MHC-II expression (MFI) in CD11b-
XCR1+ cDC1 cells in heart and lymph node and corresponding representative contour blots. Symbols represent individual mice. Error bars show mean±SEM; *P<0.05; 
**P<0.001; ***P<0.0001; ****P<0.00001 (1-way ANOVA with Dunnett multiple comparisons post hoc test comparing each time point to baseline, multiplicity-
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in WT mice (Figure 3B). A subtle but nonsignificant dif-
ference at early time points (week 2) suggested pro-
tection from acute inflammatory damage because of 
depletion of Clec9a. This has been shown previously 
in acute pancreatitis and systemic candidiasis and has 
been explained by a dampening effect on neutrophil-
mediated tissue immunopathology.49 Notably however, 
the frequency of CD11b+ myeloid cells, CD11b+Ly6g+ 
neutrophils, and CD11c+ DC among total leukocytes in 
the myocardium and lymph nodes, both at baseline and 
at week 1 after isoproterenol injection, was unaffected 
by Clec9a depletion (Figure IV in the Data Supplement).
As the focus of this study was long term immuno-
pathology, a more detailed analysis of histopathology 
Figure 3. Blockade of DC cross-priming by genetic depletion of Clec9a protects mice from immunopathology after ischemic injury.
C57BL/6J (WT) and Clec9a−/−C57BL/6J (KO) mice were treated with 160 mg/kg isoproterenol to induce T2MI-like injury and hearts were isolated for histology and 
immunohistochemistry. A, cTroponin I levels in serum of WT and KO 24 h after isoproterenol challenge. B, Mononuclear infiltrate/immunopathology and fibrosis in 
the myocardium of isoproterenol-treated WT and KO mice as assessed by quantification of nuclei in hematoxylin and eosin–stained heart sections over time (day 
0, week 2, week 4) after injury. C, Semiquantitative immunopathology score and corresponding changes per mouse strain in myocardial sections of isoproterenol-
treated WT and KO mice as assessed by hematoxylin and eosin–stained histology 4 weeks after injury. C, lower, Example micrographs per experimental group. D, 
Fibrotic area and corresponding changes per mouse strain in myocardial sections of isoproterenol-treated WT and KO mice as assessed by Picrosirius red–stained 
histology 4 weeks after injury. D, lower, Example micrographs per experimental group. Symbols represent individual mice. Error bars show mean±SEM; *P<0.05; 
**P<0.001; ***P<0.0001; ****P<0.00001 (2-way ANOVA with Sidak multiple comparisons post hoc test; 2-tailed Student t test for fold-change data [C and D] 
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was performed at later time points postinjection. Cle-
c9a−/− depletion resulted in dampened immunopa-
thology (Figure  3C) and fibrosis (Figure  3D) in mice. 
We also observed a mild distortion of healthy tissue 
morphology in these baseline Clec9a−/− mouse hearts, 
presumably because of the loss of a peripheral toler-
ance mechanism50,51 (Figure 3C and 3D). However, a 
thorough investigation of cardiac histopathology (Fig-
ure V in the Data Supplement), as well as character-
ization of the immune cell population in myocardium 
and mediastinal lymph nodes, did not reveal any sig-
nificant differences between healthy adult knockout 
(Clec9a−/−), heterozygous (Clec9a+/−), and WT (Cle-
c9a+/+) mice (Figure V in the Data Supplement) at 10 
weeks of age. Echocardiography and hematology data 
obtained from the International Mouse Phenotyping 
Consortium (available at www.mousephenotype.org) 
further confirms that young adult Clec9a−/− depleted 
mice (Clec9atm1b(KOMP)Wtsi) do not vary significantly from 
WT controls.52 This shows the necessity of a respective 
baseline control for each experimental group to control 
for batch effects, influences of animal age, or subtle 
variation of baseline phenotypes between C57BL/6J 
and Clec9a−/− strains. Both sexes showed comparable 
responses, despite a small additional protective effect 
in females (Figure VI in the Data Supplement).
In summary, inflammation and fibrosis induced by 
myocardial damage are dampened by blockade of DC 
cross-priming, presumably because of faster resolution 
of the inflammatory process despite a largely compa-
rable degree of initial injury.
Blockade of DC Cross-Priming Protects 
From Cardiac Adverse Remodeling and 
Functional Decline After Ischemic Injury 
To determine whether faster resolution of immunopa-
thology in the CLEC9a−/− mice affects cardiac morphol-
ogy and function, we analyzed ECG parameters and 
echocardiography in isoproterenol-treated Clec9a−/− 
and WT mice 2 and 4 weeks after injection, respec-
tively (Figure 4). While heart rates remained consistent 
(Figure  4A), Clec9a−/− and WT mice showed different 
functional responses to isoproterenol challenge. Quan-
tification of ECG traces (Figure  4B, scheme) revealed 
a difference in isoproterenol-induced changes in QRS 
duration, an indicator of ventricular depolarization, be-
tween WT and Clec9a−/− mice  (Figure 4C). While QRS 
duration appeared to decrease in WT mice, a subtle in-
crease was observed in Clec9a−/− mice. A summary of all 
ECG and optical mapping parameters tested is shown 
in Figure 4D.
Analysis of systolic function by parasternal echocar-
diography was performed by analyzing M-mode traces 
of 3 levels (base, mid/papillary muscle level, apex) in 
both long and short axes view (Figure 4E, scheme). This 
showed a significant drop in LV ejection fraction (EF; 
Figure 4F) which correlated with a clear dilation pheno-
type with increased LV volumes (Figure 4G) in WT mice. 
Dilation was detectable but mild in Clec9a−/− mice and 
did not translate into significantly decreased functional 
decline (Figure 4F and 4G). Thus, while the isoproter-
enol-induced decrease in EF, as well as increase  in LV 
end-diastolic LV dilation, persisted in WT mice, Clec9a−/− 
mice largely recovered normal cardiac function. Com-
prehensive echocardiography parameters are shown in 
Figure 4H.
In summary, blockade of DC cross-priming function 
not only affects histopathology after myocardial injury, 
but also impacts on function as it prevents adverse re-
modeling and corresponding functional decline of the 
heart.
Blockade of DC Cross-Priming Function 
Protects Clec9a−/− Mice From Cytotoxic 
CD8+ T Cell Activation 
To elucidate the underlying immunologic mechanism 
conveying protection from immune-mediated damage 
in Clec9a−/− mice, we performed flow cytometry on the 
T cell population in the heart and heart-draining medi-
astinal lymph nodes 2 and 4 weeks after isoproterenol-
induced ischemic cardiac injury (Figure 5A, gating).
While the relative contribution of total CD3+ and 
CD3+CD4+ T cells in the heart and mediastinal lymph 
nodes remains constant (Figure 5B), a significant shift 
toward cytotoxic CD8+ T cells in the hearts and lymph 
nodes of WT mice contrasted with an unchanged T cell 
population in Clec9a−/− mice (Figure 5B and 5C). Impor-
tantly, as previously suggested,17 depletion of CD8+ T 
cells protected mice from immune-mediated myocardial 
damage, and another recent study confirms pathogenic 
effects of CD8+ T cells after MI.18 Consistent with single 
cell sequencing data above (Figure 1H and 1I), a sig-
nificant proportion of CD3+ cells in the heart expressed 
neither CD4+ nor CD8+ (Figure 5C). The biological sig-
nificance of this finding is currently under investigation.
Importantly, mediastinal lymph node CD8+ T cells in 
WT mice displayed an activated phenotype with down-
regulated cell adhesion molecule L-selectin/CD62L. The 
proportion of CD62L-CD44- effector cells increased, 
while CD62L+CD44- naïve cells decreased. In addition, 
a shift from CD62L+CD44+ central memory to CD62L-
CD44+ effector memory was observed (Figure 5D). In 
contrast, the activation state of lymph node CD8+ T 
cells in Clec9a−/− mice remained at baseline levels (Fig-
ure 5E and 5F). This was most prominent 2 weeks after 
isoproterenol treatment (Figure VII in the Data Supple-
ment). To confirm a role of CD8+ T cells, T2MI was in-
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Figure 4. Blockade of DC cross-priming protects mice from adverse remodeling and functional decline after ischemic injury.
C57BL/6J (WT) and Clec9a−/− C57BL/6J (KO) mice were treated with 160 mg/kg isoproterenol to induce T2MI-like injury and heart function was assessed by electro-
cardiography, optical mapping and transthoracic echocardiography. A, Heart rate of isoproterenol-treated WT and KO mice 2 weeks after challenge. B, Schematic 
showing features of electrocardiography traces. C, Quantification of QRS duration in electrocardiography traces of isoproterenol-treated WT and KO mice 2 weeks 
after challenge and corresponding fold change of QRS duration in both strains. Symbols represent individual mice. D, Summary of parameters obtained by electro-
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cytotoxic T cells. Histopathologic analysis of the hearts 
was performed 4 weeks after treatment and fibrosis in 
Cd8−/− mice was decreased in comparison to WT control 
mice (Figure 5G). Thus, blockade of DC cross-priming 
ability prevents the activation of cytotoxic CD8+ T cells, 
which enhances myocardial immunopathology.
CD8+ T Cell Numbers Are Elevated in 
Human HF Tissue 
To extend these findings to human disease, LV sections 
were prepared from end-stage human HF hearts ob-
tained during transplant surgery. Remote LV areas with 
macroscopically healthy appearance were chosen to 
probe T cell infiltration into the remote myocardium. 
Control sections were prepared from donor hearts 
deemed unsuitable for transplantation. Increased num-
bers of total CD3+ T cells (Figure 6A) and CD8+ cytotoxic 
T cells (Figure  6B) were detected in human HF tissue 
with more CD3+ and CD8+ cells in 5 out of 7 (71%) 
ischemic HF patients compared with donors, confirm-
ing the relevance of myocardial CD8+ T cells in human 
HF. These results also indicate that increased myocardial 
T cell numbers are not a simple bystander effect of total 
immune cell infiltration into damaged tissue, but active 
infiltration into the otherwise healthy myocardium. Do-
nors were 3 females, 2 males (38±13 years). HF patients 
were 2 female and 5 male individuals (59±7 years) with 
end-stage HF attributable to ischemic heart disease af-
ter MI (Figure 6C). We also included 3 patients (2 fe-
males and 1 male; 33±16 years) with HF attributable to 
previous myocarditis for a comparison with heart dis-
ease of an established immunologic etiology (Figure VIII 
in the Data Supplement).
Accumulation of Cytotoxic CD8+ T Cells 
Is Reduced in Both Scarred and Remote 
Myocardium in Clec9a−/− Mice 
To further confirm the relevance of cross-priming DC in 
the recruitment of myocardial T cells into the healthy re-
mote myocardium, we induced T1MI by surgical left an-
terior descending artery ligation in both Clec9a−/− and 
WT mice. This model generates myocardial injury with 
clearly separated scar and remote areas, allowing these 
to be analyzed independently (Figure  7A). Single cell 
suspensions were generated from dissected scar and re-
mote LV tissue and analyzed for the presence of T cells 
4 weeks after infarction. While there are clearly over-
all higher CD45+ immune cell numbers in the scarred 
compared with the remote tissue, a striking reduction is 
apparent in Clec9a−/− compared with WT mice in both 
tissue areas (Figure 7B). Importantly, cytotoxic CD8+ T 
cell numbers are also clearly decreased in both areas in 
Clec9a−/− mice, while changes in CD4+ T cell numbers 
are less prominent (Figure 7B).
Using immunohistochemistry to visualize CD8+ cells 
in situ, we confirmed their presence and decrease in 
both scarred and remote areas (Figure 7C). As evident 
from histology and similar to the observations previous-
ly noted, the total number of CD8+ cytotoxic T cells per 
square millimeter of tissue was considerably (≈10-fold) 
higher in the scar compared with the remote tissue, yet 
the reduction in numbers between Clec9a−/− and WT 
mice was seen in both areas. This is also in line with 
the reduction in myocardial CD8+ T cells in Clec9a−/− 
mice the isoproterenol-induced T2MI model (Figure IX 
in the Data Supplement), where healthy (“remote”) 
and damaged areas are interlaced making separate 
analysis challenging. Notably, numbers obtained from 
total LV tissue of isoproterenol-treated T2MI hearts fall 
in between scar and remote tissue of T1MI hearts, sup-
porting that T2MI tissue is a mix of these 2 states. These 
results confirm that the depletion of DC cross-priming 
function blocks cytotoxic T cell infiltration and further 
show that this is not only true for tissue damaged dur-
ing the initial infarction (scar), but also for supposedly 
healthy remote tissue indicating autoreactive cytotoxic 
T cells infiltrating the healthy myocardium.
DISCUSSION
In this study we show a role of DC cross-priming of 
cytotoxic CD8+ T cells in the persistence of myocardial 
immunopathology and the degree of fibrosis after isch-
emic injury, resulting in exacerbation of adverse LV re-
modeling and decline in cardiac function.
Anti-heart autoreactivity of the adaptive immune 
system has been implicated in structural remodeling, 
functional decline, and the development of heart fail-
ure.21,25,53 Here we define a mechanism by showing 
that cross-priming cDC1 exacerbate immune-mediated 
damage after ischemic injury of the heart. Depletion of 
the C-type lectin-like receptor CLEC9A/DNGR-1/CD370 
blocks the cross-priming function of cDC1 and prevents 
the activation of cytotoxic CD8+ T cells likely to target 
Figure 4 Continued. (blue lines in long and short axes) showing levels of M-mode traces (base, mid, apex) and obtained measurements. F, LV global function in 
isoproterenol-treated WT and KO mice as assessed by % ejection fraction (left) and fold decrease from baseline (right). G, LV dilation in isoproterenol-treated WT 
and KO mice as assessed by LV end-systolic volume (left) and fold increase from baseline (right). H, Summary of echocardiography parameters obtained by echo-
cardiography M-mode traces from both the parasternal long- and short-axis view; n=6/group. Error bars show mean±SEM; *P<0.05; **P<0.001; ***P<0.0001; 
2-way ANOVA with Sidak multiple comparisons post hoc test (A, C, F, G); 2-tailed Student t test (C and D); repeat measures 2-way ANOVA with Sidak multiple 
comparisons post hoc test (F and G); 1-way ANOVA with Dunnett multiple comparisons post hoc test (H); multiplicity-adjusted P values. APD, action potential 
duration; ctrl, control; d, diastole; d0, day 0; dV/dt, rate of action potential rise; EDV, end diastolic volume; EF, ejection fraction; ESV; end systolic volume; FS, frac-
tional shortening; ISO, isoproterenol; IVS, interventricular septum (thickness); KO, knockout; LV, left ventricular; LVID, left ventricular internal dimension; LVPW, left 
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cardiac antigens, thus preventing persistent immune-
mediated damage.
In the cardiac context, DC ablation studies have pre-
viously yielded inconsistent results. Depletion of CD11c+ 
cells in a mouse model of acute MI led to deteriora-
tion of LV function and remodeling,24 while a recent 
study depleting DC via the transcription factor Zbtb46 
reduced infarct size, improved systolic function, and 
reduced CD3+ T cell numbers in the ischemic tissue.25 
Human data are scarce and largely based on the pres-
ence or absence of DC in selected tissues. Myocardial 
DC activation was decreased in human dilated cardio-
myopathy,54 while decreased circulating DC numbers 
correlated with decreased EF and increased LV dilation 
in chronic HF patients.55 This highlights a common com-
plication in interpreting immunologic studies; broad 
immune cell populations are not homogenous entities, 
but complex interacting networks of subpopulations 
and factors with pleiotropic effects depending on the 
specific environment and varying functional character-
istics of subpopulations are important.
The DC population in the heart is heterogenous 
already at healthy baseline conditions and includes a 
significant number of cross-priming DC, which are 
specialized in the recognition of necrotic cells.56 After 
tissue injury, they take up local antigens, migrate to 
draining lymph nodes and present processed antigens 
not only to CD4+, but also to cytotoxic CD8+ T cells. 
Cross-presenting DC may thus be central in inducing 
and boosting post-MI autoimmunity and directing T 
cell–mediated damage through autoreactive cytotoxic 
CD8+ T cells. While recent interest in the role of CD4+ 
helper T cells and their subpopulations has uncovered 
both detrimental and beneficial effects in heart dis-
ease,57,58 less is known about the role of cytotoxic CD8+ 
T cells after ischemic injury in the heart. Their patho-
genic function in viral myocarditis is established,59 and 
they are recruited to other tissues undergoing isch-
emic injury including the brain.60 CD8+ T cells isolated 
from rats with experimental MI directly killed healthy 
cardiomyocytes in vitro17 and a recent study confirms 
detrimental inflammatory activity after MI.18 Notably, 
Figure 5. Protection of Clec9a−/− mice after ischemic injury is due to a halt in activation of CD8+ T cells.
C57BL/6J (WT) and Clec9a−/− C57BL/6J (KO) mice were treated with 160 mg/kg isoproterenol to induce T2MI-like injury and flow cytometry was performed on a 
single cell preparation of the heart and mediastinal lymph nodes. Isoproterenol-treated Cd8−/− mice were used for histopathological assessment of cardiac immuno-
pathology. A, Flow cytometry contour blot showing the gating for the T cell population among total CD45+ and (B) corresponding quantification of CD3+, CD4+ and 
CD8+ cells in the heart and lymph node; n=4 to 7/group. C, Composition of the CD3+ cell population in heart and lymph nodes based on CD4 and CD8 expression. 
D, Representative contour blots of CD62L and CD44 staining in the CD8+ population of mediastinal lymph nodes of isoproterenol-treated versus control mice. E, 
Quantification of CD62L-CD44+ effector cells among total CD8+ cells in mediastinal lymph nodes. F, Composition of the CD8+ cell population in lymph nodes based 
on CD62L and CD44 expression. G, Micrographs of Picrosirius red–stained cardiac sections of isoproterenol-treated WT and Cd8−/− mice and corresponding semi-
quantitative fibrosis score. Symbols represent individual mice. Error bars show mean±SEM; *P<0.05; 2-way ANOVA with Sidak multiple comparisons post hoc test (B 
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cytotoxic effects were MHC-dependent and antigen-
specific, as cytotoxicity was significantly higher when 
using syngeneic CD8+ T cells from the same rat strain.17 
In contrast, CD8+ T cells expressing the AT2R (angioten-
sin type 2 receptor) were found to infiltrate the tissue 
surrounding the infarct zone in another rat MI model 
Figure 6. CD3+ and CD8+ T cell numbers are elevated in the myocardium of human HF patients.
Human LV tissue was obtained from end-stage HF patients during transplant surgery. Control samples for comparison were obtained from organ donor hearts assessed 
to be unsuitable for donation. Representative images and corresponding count of the number of CD3+ (A) and CD8+ (B) T cells/cm2 heart tissue section. C, Patient popu-
lation; n=5 (donors), 7 (ischemic heart disease). Symbols represent individual patients. Error bars show mean±SEM; *P<0.05; **P<0.001; ***P<0.0001 (1-tailed Student 
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Figure 7. Accumulation of cytotoxic CD8+ T cells is reduced in both scarred and remote myocardium in Clec9a−/− mice.
Type 1 myocardial infarction was induced in C57BL/6J (WT) and Clec9a−/− C57BL/6J (KO) mice by permanent ligation of the left anterior descending artery. Hearts 
were collected 4 weeks after infarction and processed for histology and flow cytometry. A, Example micrographs showing Picrosirius red– and H&E-stained type 1 
myocardial infarction heart sections above occlusion, approximately at the ligation point, and below the ligation point. B, Flow cytometry on single cell prepara-
tions of isolated scar and remote left ventricular tissue of the heart for quantification of CD3+, CD4+, and CD8+ cells/mg tissue. C, Immunohistochemistry staining 
for and quantifying numbers of CD8+ cells per mm2 scar and remote tissue section, respectively. Symbols represent individual mice. Error bars show mean±SEM; 
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and downregulate expression of proinflammatory cy-
tokines, suggesting a potential cardioprotective role of 
this subset.61 The current study documents a dominant 
CD8+ T cell population in the heart, both after ischemic 
damage in mice as well as in human HF. Importantly, 
these T cells are not only observed as part of the total 
immune cell infiltrate in damaged areas but are also 
present in remote tissue that appears healthy. This is a 
crucial indicator that these T cells did not infiltrate in 
response to the initial infarction, but rather that they 
accumulated in the healthy myocardium in response to 
myocardial antigen. Over time, their cytotoxic activity 
against cardiomyocytes will contribute to the  postin-
farction pathologic burden on the heart. Depletion of 
DC cross-priming function blocked accumulation and 
activation of CD8+ T cells correlating with decreased 
postischemic immunopathology and functional decline.
Because of their unique position as T cell inducers, 
DC are a well-established pathogenic factor in proto-
type autoimmune diseases, including type 1 diabetes 
and rheumatoid arthritis,62 and several attempts have 
been made to tolerize DC for immunomodulatory 
therapies in autoimmune conditions including post-MI 
autoimmunity.24 Identification of cross-priming DC-
mediated activation of anti-heart autoreactivity lead-
ing to exacerbation of adverse remodeling toward HF 
identifies a novel pathogenic entity leading to immune-
mediated LV dilation. Blockade of this response offers a 
promising therapeutic prospect for immunomodulation 
post-MI and during HF.
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